Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells

Tigilanol tiglate (TT, also known as EBC-46) is a novel, plant-derived diterpene ester possessing Anticancer and wound-healing properties. Here, we show that TT-evoked PKC-dependent S⁹⁸⁵ phosphorylation of the tyrosine kinase MET leads to subsequent degradation of tyrosine phosphorylated p-Y¹⁰⁰³ and p-Y^1234/5 MET species. PKC inhibition with BIM-1 blocked S⁹⁸⁵ phosphorylation of MET and led to MET cell surface accumulation. Treatment with metalloproteinase inhibitors prevented MET-ECD release into Cell Culture media, which was also blocked by PKC inhibitors. Furthermore, unbiased secretome analysis, performed using TMT-technology, identified additional targets of TT-dependent release of cell surface proteins from H357 head and neck Cancer cells. We confirm that the MET co-signalling receptor syndecan-1 was cleaved from the cell surface in response to TT treatment. This was accompanied by rapid cleavage of the cellular junction adhesion protein Nectin-1 and the nerve growth factor receptor NGFR^p75/TNFR16. These findings, that TT is a novel negative regulator of protumorigenic c-MET and NGFRp⁷⁵/TNFR16 signalling, as well as regulating Nectin-1-mediated cell adhesion, further contribute to our understanding of the mode of action and efficacy of TT in the treatment of solid tumours.

cancer; secretome analysis; therapy.